Evofem Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Evofem Biosciences (EVFM) Misses Q2 EPS by 54c
August 4, 2020 8:07 AM EDTEvofem Biosciences (NASDAQ: EVFM) reported Q2 EPS of ($0.91), $0.54 worse than the analyst estimate of ($0.37).
Second quarter and recent highlights include:
Received U.S. Food and Drug Administration (FDA) approval of Phexxi (lactic acid, citric acid and potassium bitartrate) for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception; Strengthened the balance sheet with approximately $136 million in gross proceeds from two financing transactions during an incredibly challenging... More